Crown Bioscience (China)

Recent papers from Crown Bioscience (China)

1. From Phenotypic Screening to Target and Compound Prioritization for Autosomal Dominant Polycystic Kidney DiseaseSLAS DISCOVERY · 2026
2. Optimization of a TEEDA–based initiation system for SDS–PAGEActa Biochimica Polonica · 2026
3. Experimental and Theoretical Investigation of Steel-Cross Laminated Timber Composite Beams with Grouted Shear ConnectorsJournal of Structural Engineering · 2026
4. Targeted analysis of salicylate binding partners in renal epithelial cells reveals major AMPK dependencyBiochimica et Biophysica Acta (BBA) - Molecular Cell Research · 2026
5. The molecular similarity landscape of preclinical cancer models to patient tumorsJCI Insight · 2026
6. Substance P as a potential salivary biomarker to differentiate Sjögren’s disease from non-Sjögren sicca syndrome: a pilot studyFrontiers in Immunology · 2026
7. Identification of drug repurposing candidates for the treatment of polycystic kidney diseaseBritish Journal of Pharmacology · 2026
8. Translational 3D in vitro models for immunotherapy testing: from reconstituted organoid co-culture assays to autologous ex vivo patient tissuesFrontiers in Immunology · 2026
9. Toward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome testProceedings of the National Academy of Sciences · 2026
10. Abstract 2961: Developing ADC-resistant tumor models for efficacy evaluation of next-generation anticancer therapies.Cancer Research · 2026
11. Abstract 2161: Paired PDX-PDXO models serve an integrated preclinical platform for high-throughput payload screening and ADC drug development.Cancer Research · 2026
12. Abstract 4449: Functional organoid screening uncovers target dependency and bystander killing in TROP2 ADCsCancer Research · 2026
13. Abstract 3387: Enhancing the predictability of human pharmacokinetics for antibody-drug conjugates (ADCs) using human FcRn transgenic miceCancer Research · 2026
14. Abstract 4616: Integrated organoid screening approaches enable preclinical assessment of protein degrader efficacy and target engagementCancer Research · 2026
15. Abstract 7540: Integrated multi-omics analysis reveals conserved tumor-associated antigens (TAAs) profiles in PDX and organoid models for advancing ADC developmentCancer Research · 2026
16. Abstract 5549: Non-clinical modeling the therapeutic window of HX044, a novel CTLA4xCD47 BsAbCancer Research · 2026
17. Abstract 4515: Clinically relevant AML modeling with in vitro bone marrow niche and in vivo PDX approaches.Cancer Research · 2026
18. Abstract 2177: Characterization of a panel of PDX models derived from PARP inhibitors pretreated breast and ovarian cancer patients for therapeutic evaluation.Cancer Research · 2026
19. Abstract 7679: Advanced proteomic profiling of patient-derived tumor models reveals high cross-model concordance and improved translational fidelityCancer Research · 2026
20. Abstract 4448: 3D-tumor organoid, over 2D-cell, is more predictive of in vivo anti-cancer pharmacology in assessing ADC candidatesCancer Research · 2026